AI eye scan neurological diseases detection breakthrough by Professor Rayaz Malik could transform early diagnosis and patient outcomes worldwide
A Pakistani researcher has made a breakthrough that could change how the world detects neurological diseases. Professor Rayaz Malik, a Pakistani-origin scientist at Weill Cornell Medicine–Qatar, has developed an AI-powered eye scan capable of identifying neurodegenerative diseases years before any symptoms appear. The AI eye scan neurological diseases detection tool takes just two to three minutes to complete. Moreover, it uses artificial intelligence to analyze nerve fibers in the eye with remarkable precision.
The implications for patients are profound. The scan can detect dementia at least three years before visible symptoms emerge. Furthermore, it can identify diabetic neuropathy up to five years earlier than conventional methods. Therefore, doctors could begin treatment and intervention far sooner than currently possible. Early action in neurodegenerative conditions can meaningfully slow disease progression and dramatically improve quality of life.
Medical experts have responded with considerable enthusiasm. Early detection tools of this kind could transform patient care across the world. Currently, conditions like dementia often go undetected until significant neurological damage has already occurred. However, a two-minute eye scan that predicts the disease years in advance changes that reality entirely. Furthermore, the non-invasive nature of the scan makes it accessible and practical in clinical settings.
The development has also drawn widespread attention on social media. Many have praised Professor Malik’s work as a landmark achievement for medical research and a proud moment for Pakistani science. His work at Weill Cornell Medicine–Qatar places Pakistan’s scientific contribution firmly on the global medical map.
Still, the most important measure of this breakthrough will be how quickly it reaches patients. Finally, if the technology moves from research into widespread clinical use, millions of people living with undiagnosed neurological conditions could benefit from earlier, more effective care.
